AKRO – Akero Therapeutics Inc
Name : Akero Therapeutics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $0.0000
EPSttm :
[iframe https://s.tradingview.com/embed-widget/symbol-info/?locale=in&symbol=AKRO
#%7B%22symbol%22%3A%22A%22%2C%22width%22%3A%22100%25%22%2C%22colorTheme%22%3A%22light%22%2C%22isTransparent%22%3Atrue%2C%22height%22%3A203%2C%22utm_source%22%3A%22themarketstracker.com%22%2C%22utm_medium%22%3A%22widget_new%22%2C%22utm_campaign%22%3A%22symbol-info%22%7D 900 250 ]
[iframe https://api.stockdio.com/visualization/financial/charts/v1/PricesChange?app-key=F086EEE750E14D8D8A456DB88B2D6D8C&symbol=AKRO
&conditionalVolume=false&allowPeriodChange=false&tooltipsStyle=None&palette=Financial-Light&showBorderAndTitle=false 300 200 ]
Float Short %
9.59
Margin Of Safety %
Put/Call OI Ratio
0.4
EPS Next Q Diff
-0.01
EPS Last/This Y
-0.3
EPS This/Next Y
-0.48
Price
40.04
Target Price
74.09
Analyst Recom
1
Performance Q
-19.9
Relative Volume
0.88
Beta
-0.22
Ticker: AKRO
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-04-14 | AKRO | 37.58 | 0.44 | 1.10 | 25496 |
| 2025-04-15 | AKRO | 38.08 | 0.47 | 0.06 | 32440 |
| 2025-04-16 | AKRO | 37.45 | 0.47 | 0.15 | 32546 |
| 2025-04-17 | AKRO | 37.64 | 0.43 | 0.00 | 31662 |
| 2025-04-18 | AKRO | 37.63 | 0.43 | 0.06 | 31662 |
| 2025-04-21 | AKRO | 37.7 | 0.47 | 0.06 | 19493 |
| 2025-04-22 | AKRO | 38.5 | 0.46 | 0.09 | 19613 |
| 2025-04-23 | AKRO | 39.58 | 0.44 | 0.07 | 21032 |
| 2025-04-24 | AKRO | 41 | 0.41 | 0.03 | 22241 |
| 2025-04-25 | AKRO | 41 | 0.38985908707696 | 0.048027444253859 | 23080 |
| 2025-04-28 | AKRO | 42.17 | 0.3853412462908 | 0.0009891197 | 23343 |
| 2025-04-29 | AKRO | 43 | 0.37 | 0.03 | 24169 |
| 2025-04-30 | AKRO | 45.58 | 0.35 | 0.04 | 25144 |
| 2025-05-01 | AKRO | 45.28 | 0.35 | 3.78 | 25292 |
| 2025-05-02 | AKRO | 44.91 | 0.51 | 0.04 | 28950 |
| 2025-05-05 | AKRO | 44.96 | 0.52 | 0.77 | 28991 |
| 2025-05-06 | AKRO | 42.06 | 0.49 | 0.02 | 32109 |
| 2025-05-07 | AKRO | 42.76 | 0.46 | 0.02 | 33859 |
| 2025-05-08 | AKRO | 42.37 | 0.44 | 0.10 | 34884 |
| 2025-05-09 | AKRO | 39.8 | 0.43 | 0.05 | 35414 |
| 2025-05-12 | AKRO | 41.58 | 0.41 | 0.04 | 36793 |
| 2025-05-13 | AKRO | 40.04 | 0.40 | 1.80 | 37296 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-04-14 | AKRO | 37.60 | -10.2 | -131.2 | -4.05 |
| 2025-04-15 | AKRO | 38.08 | -10.2 | -111.6 | -4.05 |
| 2025-04-16 | AKRO | 37.45 | -10.2 | -98.1 | -4.05 |
| 2025-04-17 | AKRO | 37.63 | -10.2 | -108.0 | -4.05 |
| 2025-04-18 | AKRO | 37.63 | -10.2 | -105.8 | -4.05 |
| 2025-04-21 | AKRO | 37.71 | -10.2 | -106.8 | -4.05 |
| 2025-04-22 | AKRO | 38.50 | -10.2 | -115.9 | -4.05 |
| 2025-04-23 | AKRO | 39.61 | -10.2 | -119.0 | -4.05 |
| 2025-04-24 | AKRO | 40.95 | -10.2 | -121.1 | -4.05 |
| 2025-04-25 | AKRO | 41.00 | -10.2 | -105.8 | -4.05 |
| 2025-04-28 | AKRO | 42.17 | -10.2 | -118.6 | -4.05 |
| 2025-04-29 | AKRO | 43.04 | -10.2 | -115.0 | -4.05 |
| 2025-04-30 | AKRO | 45.61 | -10.2 | -131.9 | -4.05 |
| 2025-05-01 | AKRO | 45.31 | -10.2 | -102.9 | -4.05 |
| 2025-05-02 | AKRO | 44.87 | -10.2 | -102.0 | -4.05 |
| 2025-05-05 | AKRO | 44.93 | -10.2 | -106.4 | -4.05 |
| 2025-05-06 | AKRO | 42.05 | -10.2 | -77.7 | -4.05 |
| 2025-05-07 | AKRO | 42.79 | -10.2 | -114.0 | -4.05 |
| 2025-05-08 | AKRO | 42.38 | -10.2 | -101.5 | -4.05 |
| 2025-05-09 | AKRO | 39.85 | -10.2 | -79.0 | -4.05 |
| 2025-05-12 | AKRO | 41.53 | -10.2 | -124.5 | -4.05 |
| 2025-05-13 | AKRO | 40.04 | -10.2 | -89.7 | -4.05 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-04-14 | AKRO | -4.41 | -1.06 | 7.76 |
| 2025-04-15 | AKRO | -4.41 | -1.06 | 7.76 |
| 2025-04-16 | AKRO | -4.41 | -1.06 | 7.76 |
| 2025-04-17 | AKRO | -3.88 | -1.06 | 7.76 |
| 2025-04-18 | AKRO | -3.88 | -1.06 | 7.76 |
| 2025-04-21 | AKRO | -2.92 | -1.42 | 7.76 |
| 2025-04-22 | AKRO | -2.93 | -1.42 | 7.76 |
| 2025-04-23 | AKRO | -2.93 | -1.42 | 7.76 |
| 2025-04-24 | AKRO | -2.93 | -1.42 | 7.76 |
| 2025-04-25 | AKRO | -2.93 | -1.42 | 7.76 |
| 2025-04-28 | AKRO | -2.93 | -1.32 | 8.92 |
| 2025-04-29 | AKRO | -3.00 | -1.32 | 8.92 |
| 2025-04-30 | AKRO | -3.00 | -1.32 | 8.92 |
| 2025-05-01 | AKRO | -3.00 | -1.32 | 8.92 |
| 2025-05-02 | AKRO | -2.79 | -1.32 | 8.92 |
| 2025-05-05 | AKRO | -2.79 | -0.51 | 8.92 |
| 2025-05-06 | AKRO | -1.07 | -0.51 | 8.92 |
| 2025-05-07 | AKRO | -1.07 | -0.51 | 8.92 |
| 2025-05-08 | AKRO | -1.07 | -0.51 | 8.92 |
| 2025-05-09 | AKRO | -1.10 | -0.51 | 8.92 |
| 2025-05-12 | AKRO | -1.19 | -0.00 | 9.59 |
| 2025-05-13 | AKRO | -1.19 | -0.00 | 9.59 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
[iframe https://widget.finnhub.io/widgets/historical-eps?symbol=AKRO
589 360 ]
Last Quarter Act. EPS
-0.99
Avg. EPS Est. Current Quarter
-0.99
Avg. EPS Est. Next Quarter
-1
Insider Transactions
-1.19
Institutional Transactions
Beta
-0.22
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
16
Growth Score
20
Sentiment Score
18
Actual DrawDown %
31.4
Max Drawdown 5-Year %
-80
Target Price
74.09
P/E
Forward P/E
PEG
P/S
P/B
2.94
P/Free Cash Flow
EPS
-3.75
Average EPS Est. Cur. Y
-4.05
EPS Next Y. (Est.)
-4.53
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
0.88
Return on Equity vs Sector %
-57.3
Return on Equity vs Industry %
-40.3
EPS 1 7Days Diff
0.2
EPS 1 30Days Diff
0.79
EBIT Estimation
-89.7
[iframe https://widget.finnhub.io/widgets/recommendation?symbol=AKRO
589 450 ]
[iframe https://widget.finnhub.io/widgets/eps-estimate?symbol=AKRO
589 450 ]
Akero Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 69
Akero Therapeutics, Inc. engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
stock quote shares AKRO – Akero Therapeutics Inc Stock Price stock today
news today AKRO – Akero Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch AKRO – Akero Therapeutics Inc yahoo finance google finance
stock history AKRO – Akero Therapeutics Inc invest stock market
stock prices AKRO
premarket after hours
ticker AKRO
fair value insiders trading